Ensign Peak Advisors, Inc Cerevel Therapeutics Holdings, Inc. Transaction History

Ensign Peak Advisors, Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$20.27 - $42.44 $757,388 - $1.59 Million	37,365 Added 127.57%	66,655 $2.83 Million
Q4 2022 Feb 13, 2023	BUY	$25.35 - $31.96 $306,735 - $386,716	12,100 Added 70.39%	29,290 $923,000
Q3 2022 Nov 14, 2022	BUY	$25.5 - $41.42 $141,270 - $229,466	5,540 Added 47.55%	17,190 $486,000
Q2 2022 Aug 12, 2022	SELL	$20.62 - $37.15 $1.47 Million - $2.64 Million	-71,159 Reduced 85.93%	11,650 $308,000
Q4 2021 Feb 11, 2022	BUY	$29.21 - $44.64 $340,296 - $520,056	11,650 Added 16.37%	82,809 $2.69 Million
Q1 2021 May 12, 2021	BUY	$12.37 - $17.74 $880,236 - $1.26 Million	71,159 New	71,159 $977,000

5.01M

3.3K

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ensign Peak Advisors, Inc with notifications on news.